Long-acting glucagon-like peptide-1 receptor agonist-status December 2018

被引：16
|
作者：
Holst, Jens Juul [1 ,2 ]
机构：
[1] Univ Copenhagen, Panum Inst, Dept Biomed Sci, DK-220 Copenhagen, Denmark
[2] Univ Copenhagen, Panum Inst, NNF Ctr Basic Metab Res, DK-220 Copenhagen, Denmark
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷 / 05期
关键词：
BETA-CELL FUNCTION; GLP-1; RECEPTOR; CARDIOVASCULAR OUTCOMES; HEART-FAILURE; DOUBLE-BLIND; FOOD-INTAKE; TYPE-2; LIRAGLUTIDE; GLUCOSE; SEMAGLUTIDE;
D O I：
10.21037/atm.2019.01.09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist
    Pan, CQ
    Buxton, JM
    Yung, SL
    Tom, I
    Yang, L
    Chen, HX
    MacDougall, M
    Bell, A
    Claus, TH
    Clairmont, KB
    Whelan, JP
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (18) : 12506 - 12515
  • [2] Preclinical Effects of Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, Compared with Liraglutide and Dulaglutide
    Trautmann, Michael E.
    Choi, In Young
    Kim, Jung Kuk
    Sorli, Christopher H.
    DIABETES, 2018, 67
  • [3] Preclinical effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist, compared with liraglutide and dulaglutide
    Trautmann, M.
    Choi, I.
    Kim, I.
    Sorli, C.
    DIABETOLOGIA, 2018, 61 : S346 - S346
  • [4] A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
    Gurung, Tara
    Shyangdan, Deepson S.
    O'Hare, Joseph Paul
    Waugh, Norman
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2015, 8 : 363 - 386
  • [5] Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
    Uccellatore, Annachiara
    Genovese, Stefano
    Dicembrini, Ilaria
    Mannucci, Edoardo
    Ceriello, Antonio
    DIABETES THERAPY, 2015, 6 (03) : 239 - 256
  • [6] Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
    Annachiara Uccellatore
    Stefano Genovese
    Ilaria Dicembrini
    Edoardo Mannucci
    Antonio Ceriello
    Diabetes Therapy, 2015, 6 : 239 - 256
  • [7] In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist
    Jones, Ben
    Burade, Vinod
    Akalestou, Elina
    Manchanda, Yusman
    Ramchunder, Zenouska
    Carrat, Gaelle
    Nguyen-Tu, Marie-Sophie
    Marchetti, Piero
    Piemonti, Lorenzo
    Leclerc, Isabelle
    Thennati, Rajamannar
    Vilsboll, Tina
    Thorens, Bernard
    Tomas, Alejandra
    Rutter, Guy A.
    DIABETES OBESITY & METABOLISM, 2022, 24 (11): : 2090 - 2101
  • [8] A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy
    Knop, Filip K.
    Urva, Shweta
    Rettiganti, Mallikarjuna
    Benson, Charles T.
    Roell, William C.
    Mather, Kieren J.
    Haupt, Axel
    Pratt, Edward John
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5474 - 5478
  • [9] Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist-Immunogenicity Profile Based on Preclinical and Clinical Studies
    Del Prato, Stefano
    Choi, In Young
    Kang, Jahoon
    Trautmann, Michael E.
    Yoon, Kun-Ho
    Sorli, Christopher H.
    DIABETES, 2018, 67
  • [10] Novel mono-lipidated dimeric glucagon-like peptide-1 receptor agonist with improved long-acting and hypoglycemic activity
    Sun, Lidan
    Han, Jing
    Chen, Xinyu
    Han, Yue
    Wu, Lingling
    Xia, E.
    RSC ADVANCES, 2019, 9 (17) : 9654 - 9662
12345